View Older Stories View More Recent Stories

Jun 8, 2022 04:01PM Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 6, 2022 09:30AM Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
Jun 6, 2022 08:30AM Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022
May 24, 2022 09:40PM Neurocrine Biosciences Announces Repurchase of Convertible Notes
May 23, 2022 08:31AM Neurocrine Biosciences (NBIX) Presents INGREZZA Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms
May 23, 2022 08:30AM Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
May 13, 2022 05:50AM Neurocrine Biosciences (NBIX) Granted FDA Orphan Drug Designation for Valbenazine
May 12, 2022 07:37PM Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
May 2, 2022 08:30AM Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
Nov 22, 2021 08:00AM Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Feb 2, 2021 04:02PM Voyager Therapeutics (VYGR) Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Feb 2, 2021 04:01PM Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Dec 22, 2020 04:20PM Voyager (VYGR) announces FDA has notified Neurocrine (NBIX) that it has placed clinical hold on RESTORE-1 clinical trial of NBIb-1817
Dec 22, 2020 04:17PM Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
Sep 11, 2020 11:36AM Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
Sep 11, 2020 11:33AM Neurocrine Bio (NBIX), Voyager (VYGR) Present New L-T 3-Year Data Demonstrating that One-Time Treatment with Investigational Gene Therapy Showed Sustained Improvement in Motor Function
Sep 11, 2020 11:32AM Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
May 29, 2020 04:15PM AbbVie (ABBV), Neurocrine (NBIX) Announce FDA Approves First Oral Medication for Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 29, 2020 04:14PM FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
Aug 5, 2019 08:30AM AbbVie (ABBV) Submits NDA to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Aug 5, 2019 08:30AM AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
May 6, 2019 05:44AM Neurocrine Biosciences (NBIX), Voyager Therapeutics, Inc. (VYGR) Report Phase I Results for VY-AADC in Patients with Parkinson's Disease at AAN 2019 Meetings
May 5, 2019 09:05AM Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
Mar 28, 2019 04:15PM Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Nov 14, 2018 05:40PM AbbVie (ABBV) Presents Positive Phase 3 Data Showing Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at AAGL
Nov 14, 2018 05:35PM AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
Oct 9, 2018 04:02PM Neurocrine Biosciences (NBIX), Jnana Therapeutics Enter Strategic Collaboration
Oct 9, 2018 04:01PM Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
Sep 18, 2018 07:09AM BioTime (BTX) Names Brian Culley as CEO
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Sep 18, 2018 07:00AM BioTime Implements New Leadership Structure; Appoints Brian Culley as Chief Executive Officer
Aug 22, 2018 08:33AM AbbVie (ABBV), Neurocrine (NBIX) Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Aug 22, 2018 08:30AM AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Jul 24, 2018 08:31AM AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Secure FDA Approval of ORILISSA (elagolix)
Jul 24, 2018 08:30AM AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr 27, 2018 08:00AM AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 10, 2018 08:15AM AbbVie (ABBV), Neurocrine Biosciences (NBIX) Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Apr 10, 2018 08:15AM AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Mar 13, 2018 08:01AM AbbVie (ABBV) Says Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Primary Endpoint
Mar 13, 2018 08:00AM AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Feb 21, 2018 08:01AM AbbVie (ABBV) Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids Met Its Primary Endpoint
Feb 21, 2018 08:00AM AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Nov 1, 2017 12:00PM AbbVie (ABBV) Announces Positive Phase 3 Extension Study Data for Elagolix for Management of Endometriosis with Associated Pain
Nov 1, 2017 12:00PM AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Oct 27, 2017 07:01AM AbbVie (ABBV) Announces FDA Priority Review for Elagolix for Management of Endometriosis with Associated Pain
Oct 27, 2017 07:00AM AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Sep 6, 2017 08:02AM AbbVie (ABBV) Submits NDA to FDA for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Sep 6, 2017 08:01AM AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
May 17, 2017 12:01PM AbbVie (ABBV) Presents Phase 3 Data on Elagolix at World Congress on Endometriosis
May 17, 2017 12:00PM AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
View More Recent Stories View Older Stories